Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 12;21(1):3.
doi: 10.1007/s11892-020-01368-y.

Novel Immunomodulatory Approaches for Porcine Islet Xenotransplantation

So-Hee Hong  1   2   3   4   5 , Hyun-Je Kim  1   2   3 , Seong-Jun Kang  1   2   5 , Chung-Gyu Park  6   7   8   9   10   11
Affiliations
Review

Novel Immunomodulatory Approaches for Porcine Islet Xenotransplantation

So-Hee Hong et al. Curr Diab Rep. .

Abstract

Purpose of review: Porcine islet xenotransplantation is a promising alternative to overcome the shortage of organ donors. For the successful application of islet xenotransplantation, robust immune/inflammatory responses against porcine islets should be thoroughly controlled. Over the last few decades, there have been numerous attempts to surmount xenogeneic immune barriers. In this review, we summarize the current progress in immunomodulatory therapy for the clinical application of porcine islet xenotransplantation.

Recent findings: Long-term graft survival of porcine islets was achieved by using anti-CD154 Ab-based regimens in a preclinical non-human primate (NHP) model. However, owing to a serious complication of thromboembolism in clinical trials, the development of an anti-CD154 Ab-sparing immunosuppressant procedure is required. The efficacy of new immunosuppressive practices that employ anti-CD40 Abs or other immunosuppressive reagents has been tested in a NHP model to realize their utility in porcine islet xenotransplantation. The recent progress in the development of immunomodulatory approaches, including the immunosuppressive regimen, which enables long-term graft survival in a pig-to-non-human primate islet xenotransplantation model, with their potential clinical applicability was reviewed.

Keywords: Immune rejection; Immunosuppressant; Islet xenotransplantation; Porcine islet.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Pugliese A. Autoreactive T cells in type 1 diabetes. J Clin Invest. 2017;127(8):2881–91. https://doi.org/10.1172/JCI94549 . - DOI - PubMed - PMC
    1. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8. https://doi.org/10.1056/NEJM200007273430401 . - DOI - PubMed
    1. Vantyghem MC, Defrance F, Quintin D, Leroy C, Raverdi V, Prevost G, et al. Treating diabetes with islet transplantation: lessons from the past decade in Lille. Diabetes Metab. 2014;40(2):108–19. https://doi.org/10.1016/j.diabet.2013.10.003 . - DOI - PubMed
    1. Lablanche S, Borot S, Wojtusciszyn A, Bayle F, Tetaz R, Badet L, et al. Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French GRAGIL network. Diabetes Care. 2015;38(9):1714–22. https://doi.org/10.2337/dc15-0094 . - DOI - PubMed
    1. de Kort H, de Koning EJ, Rabelink TJ, Bruijn JA, Bajema IM. Islet transplantation in type 1 diabetes. BMJ. 2011;342:d217. https://doi.org/10.1136/bmj.d217 . - DOI - PubMed

Publication types

LinkOut - more resources